25 314

Cited 20 times in

Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy.

You, SJ; Jung, DE; Kim, HD; Lee, HS; Kang, HC
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 12(4):314-320, 2008
Journal Title
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
PURPOSE: To evaluate the efficacy and safety of adjunctive prednisolone therapy in children with cryptogenic epileptic encephalopathy, other than infantile spasms, and to determine its prognosis. METHODS: Prednisolone, 2mg/kg per day for 6 weeks, tapered for a further 2 weeks, was given in combination with previously prescribed antiepileptic drugs. A retrospective assessment of 41 children thus treated included measurements of seizure frequency, electroencephalographic findings, global assessments of cognitive function, and adverse drug events. Long-term patient prognoses over a mean follow-up period of 3 years and 5 months (range, 14-90 months) were also examined. RESULTS: Of 41 patients, 32 had Lennox-Gastaut syndrome, 4 had Doose syndrome, 1 had Otahara syndrome, 2 had Landau-Kleffner syndrome, and 2 had other unspecified generalized epilepsies. After prednisolone therapy, 73% (30/41) of patients showed a reduction in seizure frequency of >50%, and 59% (24/41) became seizure free. However, only seven patients (four with Lennox-Gastaut syndrome, two with Doose syndrome, and one with unspecified generalized epilepsy) who became seizure free remained free of seizures at the time of the final follow-up. Electroencephalographic findings and global assessments of cognitive function correlated well with seizure outcomes. No significant demographic factors influenced the efficacy of prednisolone or patient prognoses after prednisolone tapering. Most adverse events were transient, or were tolerated well with conservative management, with maintenance of the medication. CONCLUSION: Prednisolone therapy may be a safe and effective adjunct in patients with cryptogenic epileptic encephalopathies, but the high relapse rate is of concern.
MeSH terms
Anticonvulsants/administration & dosageAnticonvulsants/therapeutic useChildChild, PreschoolCognition/drug effectsCognition/physiologyDrug Therapy, CombinationElectroencephalographyEpilepsies, Myoclonic/drug therapy*Epilepsies, Myoclonic/physiopathologyEpilepsies, Myoclonic/psychologyEpilepsy/drug therapy*Epilepsy/physiopathologyEpilepsy/psychologyFemaleFollow-Up StudiesGastrointestinal Hemorrhage/chemically inducedGlucocorticoids/administration & dosageGlucocorticoids/adverse effectsGlucocorticoids/therapeutic useHumansHypertension/chemically inducedInfantLandau-Kleffner Syndrome/drug therapyLandau-Kleffner Syndrome/physiopathologyLandau-Kleffner Syndrome/psychologyMalePrednisolone/administration & dosagePrednisolone/adverse effectsPrednisolone/therapeutic use*PrognosisRetrospective StudiesSeizures/drug therapySeizures/physiopathologySeizures/psychologySepsis/chemically inducedSurvival AnalysisTreatment Outcome
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pediatrics & Adolescent Medicine
AJOU Authors
Full Text Link
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.